A synthetic peptide that acts at the growth hormone secretagogue receptor (GHS-R1a).
Research focus
Growth hormone release.
Endocrine signaling and recovery physiology.
Possible effects on body composition.
Important: Evidence demonstrating meaningful long-term body composition or recovery benefits in humans remains limited.
How it works
How the combination is designed to work
This combination brings together tesamorelin's GHRH receptor activity with ipamorelin's ghrelin receptor selectivity, addressing two distinct arms of growth hormone regulation in one prescription.
01The two peptides act at different receptors, which practitioners describe as additive: one amplifies the releasing signal, the other the secretory pulse, with minimal impact on cortisol or prolactin.
Tesamorelin / Ipamorelin: proposed mechanism, physiology, and reported clinical effects. Educational illustration — not a treatment guarantee.
Show illustration: Tesamorelin / Ipamorelin
Tesamorelin / Ipamorelin: proposed mechanism, physiology, and reported clinical effects. Educational illustration — not a treatment guarantee.
What has been studied
Potential applications and evidence
These areas are commonly discussed within wellness-focused protocols. They are educational statements, not medical claims or guarantees of outcome.
Explored for visceral fat and body composition
Discussed for recovery and sleep depth
Potential support for lean mass retention
Monitored with IGF-1 and metabolic labs
Doctor-guided
A personalized approach
Your doctor determines the final testing requirements for Tesamorelin / Ipamorelin after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.
Bloodwork status: Baseline Labs Generally Required
Commonly reviewed at baseline
IGF-1
Comprehensive metabolic panel (CMP)
Fasting glucose and A1c
Lipid panel
Thyroid panel (TSH, free T4)
Follow-up & monitoring
IGF-1 with fasting glucose and A1c at roughly 8 to 12 weeks, with dose adjustment based on the result.
Medication review
Your doctor reviews all prescriptions, supplements, and over-the-counter medications during intake before anything is prescribed.
Format & dosing
Nightly subcutaneous injection. Cycle length and dosing are determined by your doctor following intake and lab review.
Safety
What patients should know
Compounded, not FDA-approved. Contraindicated with active malignancy. Glucose and IGF-1 monitoring generally advised.
Who may not be a candidate
Pregnancy or nursing
Active malignancy without oncology clearance
Known hypersensitivity to the preparation
Active pituitary disease
Uncontrolled diabetes
Regulatory status: Compounded. Evidence level: Moderate. Eligibility, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed doctor after review of your history.